Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ryan Geschwindt"'
Autor:
Michael Smith, Ignacio Garrido-Laguna, Aung Naing, Lance Leopold, Jason J Luke, Kai Ding, Solmaz Sahebjam, Ryan Geschwindt, John D Powderly, John J Nemunaitis, Aaron S Mansfield, Wells A Messersmith, Patricia M LoRusso, Jordan D Berlin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background This phase I multicenter study was designed to evaluate the safety, tolerability, efficacy, and translational effects on the tumor microenvironment of itacitinib (Janus-associated kinase 1 (JAK1) inhibitor) in combination with epacadostat
Externí odkaz:
https://doaj.org/article/5301f58ebe1d4437ac949bf2e4df972b
Autor:
Rebecca Kristeleit, Howard Burris, Kristen Spencer, Sarina Piha-Paul, Hans Prenen, Tara Mitchell, David Pinato, Solmaz Sahebjam, Donna Graham, Nuria Kotecki, Eric Van Cutsem, Brant Delafontaine, Thomas Karasic, Jeannie Daniel, Kevin O’Hayer, Ryan Geschwindt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7ed5aa6600e64e098a5e3fe1502b2f72
Autor:
Jason J. Luke, Marwan Fakih, Charles Schneider, E. Gabriela Chiorean, Johanna Bendell, Rebecca Kristeleit, Razelle Kurzrock, Sarah P. Blagden, Irene Brana, Laura W. Goff, Kevin O’Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Publikováno v:
Scientia
Background Indoleamine 2,3-dioxygenase 1 (IDO1), an interferon-inducible enzyme, contributes to tumor immune intolerance. Immune checkpoint inhibition may increase interferon levels; combining IDO1 inhibition with immune checkpoint blockade represent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a86bc969a7907b279383b86ec75a315
https://hdl.handle.net/11351/9837
https://hdl.handle.net/11351/9837
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bbcf100cd3199695d65a7a2d3df77e
https://doi.org/10.1158/2159-8290.22540981.v1
https://doi.org/10.1158/2159-8290.22540981.v1
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170fab3f863c9be0aad6f9e19f25879b
https://doi.org/10.1158/2159-8290.22540984.v1
https://doi.org/10.1158/2159-8290.22540984.v1
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Blocking the activity of the programmed cell death protein 1 (PD-1) inhibitory receptor with therapeutic antibodies against either the ligand (PD-L1) or PD-1 itself has proven to be an effective treatment modality for multiple cancers. Contrasting wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6486db56a65286928bd5907136280e12
https://doi.org/10.1158/2159-8290.c.6549529
https://doi.org/10.1158/2159-8290.c.6549529
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5739e2f7911a281a155113d1f5d765bd
https://doi.org/10.1158/2159-8290.22540987
https://doi.org/10.1158/2159-8290.22540987
Autor:
Christophe Le Tourneau, Sarina Piha-Paul, Hans Prenen, Brant Delafontaine, David Pinato, Armando Santoro, Rebecca Kristeleit, Kristen Spencer, Tara Gangadhar, Howard Burris, Nuria Kotecki, Bristi Basu, Donna Graham, Anna Maria Di Giacomo, Solmaz Sahebjam, Massimo Di Nicola, Carlos Gomez-Roca, Pascale Tomasini, Paolo Ascierto, Giuseppe Curigliano, Thomas Karasic, Ryan Geschwindt, Jeannie Daniel, Eric Van Cutsem
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4900fe963b2edfe2b3b8842c3c02d6
https://doi.org/10.1136/jitc-2022-sitc2022.0774
https://doi.org/10.1136/jitc-2022-sitc2022.0774
Autor:
Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin
Publikováno v:
Journal for immunotherapy of cancer. 10(3)
BackgroundThis phase I multicenter study was designed to evaluate the safety, tolerability, efficacy, and translational effects on the tumor microenvironment of itacitinib (Janus-associated kinase 1 (JAK1) inhibitor) in combination with epacadostat (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b7b73fdd93a2428d2d84444b8331dc
https://pubmed.ncbi.nlm.nih.gov/36283739
https://pubmed.ncbi.nlm.nih.gov/36283739
Autor:
Holly K. Koblish, Liangxing Wu, Liang-Chuan S. Wang, Phillip C.C. Liu, Richard Wynn, Jonathan Rios-Doria, Susan Spitz, Hao Liu, Alla Volgina, Nina Zolotarjova, Kanishk Kapilashrami, Elham Behshad, Maryanne Covington, Yan-ou Yang, Jingwei Li, Sharon Diamond, Maxim Soloviev, Kevin O'Hayer, Stephen Rubin, Chrysi Kanellopoulou, Gengjie Yang, Mark Rupar, Darlise DiMatteo, Luping Lin, Christina Stevens, Yue Zhang, Pramod Thekkat, Ryan Geschwindt, Cindy Marando, Swamy Yeleswaram, Jeff Jackson, Peggy Scherle, Reid Huber, Wenqing Yao, Gregory Hollis
Publikováno v:
Cancer discovery. 12(6)
Blocking the activity of the programmed cell death protein 1 (PD-1) inhibitory receptor with therapeutic antibodies against either the ligand (PD-L1) or PD-1 itself has proven to be an effective treatment modality for multiple cancers. Contrasting wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1edc691e5bee58f1e078904d62844967
https://pubmed.ncbi.nlm.nih.gov/35652219
https://pubmed.ncbi.nlm.nih.gov/35652219